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ABSTRACT 
Ndel1 is a DISC1-interacting oligopeptidase, which cleaves neuropeptides as 
neurotensin and bradykinin, and has been associated with both neuronal 
migration and neurite outgrowth. We previously reported that plasma Ndel1 
enzyme activity is lower in patients with schizophrenia (SCZ) compared to 
healthy controls (HCs). To our knowledge, no previous study has investigated 
the genetic factors associated with the plasma Ndel1 enzyme activity. In the 
current analyses, samples from 83 SCZ patients and 92 control subjects that 
were assayed for plasma Ndel1 enzyme activity were genotyped on Illumina 
Omni Express arrays. A genetic relationship matrix using genome-wide 
information was then used for ancestry correction, and association statistics 
were calculated genome-wide. Ndel1 enzyme activity was significantly lower 
in patients with SCZ (t = 4.9; p < 0.001) and was found to be associated with 
CAMK1D, MAGI2, CCDC25, and GABGR3 at a level of suggestive 
significance (p <10-6), independent of the clinical status. Then, we performed 
a model to investigate the observed differences for case/control measures. 2 
SNPs at region 1p22.2 reached the p <10-7 level. ZFPM2 and MAD1L1 were 
the only two genes with more than one hit at 10-6 order of p value. Therefore, 
Ndel1 enzyme activity is a complex trait influenced by many different genetic 
variants that may contribute to SCZ physiopathology. 
  
INTRODUCTION 
Schizophrenia (SCZ) is a neurodevelopmental disorder resulting from 
dynamic phase-specific interplays of genetic and environmental factors, which 
may lead to disruption of normal brain assembly and function (Murray and 
Lewis, 1987; Weinberger, 1987). Heritability estimates are high, i.e. from 73-
90% (Sullivan et al., 2003) and, more recently, Genome-Wide Association 
Studies (GWAS) have implicated many genes and pathways in SCZ 
pathoetiology (Schizophrenia Working Group of the Psychiatric Genomics 
Consortium, 2014). 
Nuclear-distribution element-like 1 (Ndel1) oligopeptidase belongs to a 
class of enzymes that cleaves peptides but not proteins (Barrett and Rawlings, 
1992; Camargo et al., 1979). Ndel1 is a cytosolic protein able to bind and form 
complexes with several cytoskeleton proteins with implication in neuronal 
migration and neuritogenesis (Brandon et al., 2004; Hayashi et al., 2010; 
Kamiya et al., 2006). The NDEL1 gene is located at chromosome 17q13.1 
comprising 10 exons (Guerreiro et al., 2005), which encodes a protein with a 
coiled-coil domain at its N-terminal end and with oligopeptidase activity 
related to its C-terminal portion (Hayashi et al., 2010; Hayashi et al., 2005; 
Zylkiewicz et al., 2011). The full-length protein is 345 amino acids long and 
the enzyme active site contains a critical reactive cysteine residue at position 
273 (Hayashi et al., 2010; Hayashi et al., 2005; Zylkiewicz et al., 2011). This 
active cysteine residue and the N-terminal coiled-coil domain were both 
shown to be essential for Ndel1 function (Hayashi et al., 2010; Hayashi et al., 
2005; Zylkiewicz et al., 2011). Alternatively spliced transcript variants 
encoding multiple isoforms were also observed for this gene (Bradshaw et al., 
2009). 
Several lines of evidence also support a role for Ndel1 in SCZ. Ndel1 
was shown to be the major ligand of Disc1, a familial genetic liability gene for 
major psychiatric disorders (Brandon et al., 2004; Camargo et al., 2007). 
Disc1/Ndel1 interaction regulates neuronal morphogenesis and positioning 
during neuronal integration (Duan et al., 2007). Ndel1 and Disc1 depletion in 
newly generated adult hippocampal neurons share characteristics including 
deficits in neuronal positioning (Duan et al., 2007; Kamiya et al., 2005; Sasaki 
et al., 2005). Ndel1 knockdown prior to the differentiation of PC12 to neuronal 
cells is reported to result in inhibition of neurite outgrowth, rescued by 
enzymatically active wild-type Ndel1, but not by a mutant form of Ndel1 
(LE266/267AA) that cannot bind Disc1 (Brandon et al., 2004) or a 
enzymatically-inactive mutant form of Ndel1 (C273A) that can bind Disc1 
(Hayashi et al., 2010). The Disc1/Ndel1 interaction also competitively inhibits 
Ndel1 oligopeptidase activity (Hayashi et al., 2010). Finally, the balanced 
translocation disrupting the DISC1 gene described by Millar et al. (2000) 
generates a truncated form of Disc1 protein reported to be unable to bind to 
Ndel1 (Hayashi et al., 2005; Kamiya et al., 2005; Pletnikov et al., 2008).  
Previous studies investigating Ndel1 in SCZ have largely focused on its 
interaction with Disc1, with significant results only when haplotypes or 
interaction with Disc1 was considered (Burdick et al., 2008; Nicodemus et al., 
2010). There are mixed results for Ndel1 main effects (Kahler et al., 2008; 
Tomppo et al., 2009). In addition, Lipska et al. (2006) reported a reduced 
expression level of Ndel1, which was shown to be significantly influenced by 
DISC1 genotype, in the hippocampus of patients. 
Recently, our group showed that Ndel1 enzyme activity was significantly 
reduced in plasma of patients with SCZ compared to healthy controls (HCs) 
(Gadelha et al., 2013). Specifically, lowest Ndel1 enzyme activity values were 
found in more severe hebephrenic and treatment resistant patients. However, 
little is known about the determinants of the plasma Ndel1 enzyme activity 
levels. Herein, our main objective is to investigate by GWAS, the genomic 
variants correlated with the plasma Ndel1 enzyme activity measures. 
 
METHODS 
Study participants 
In this study, 189 subjects, 87 patients with schizophrenia (SCZ) and 
102 healthy controls (HCs), were enrolled. Outpatients were recruited from 
the Schizophrenia Program (PROESQ) of the Universidade Federal de São 
Paulo (UNIFESP). The Structured Clinical Interview for Diagnosis on DSM-IV 
(SCID) was applied by trained psychiatrists. All study participants gave 
informed consent for the study. 
Patient inclusion criteria: 1) Between 16 and 65 years old; 2) Diagnosis 
of SCZ or Schizoaffective Disorder; 3) >one year of follow-up. Healthy 
controls were selected matching on age, gender and educational level via a 
governmental unemployment office. HC inclusion criteria were: 1) Age 
between 16 and 65 years old; 2) No current or lifetime psychiatric diagnosis; 
3) Absence of known family (at any degree) history of psychosis. For both 
groups exclusion criteria were: 1) Diagnosis of hypertension; 2) Use of any 
anti-hypertensive medication, even those prescribed for other reasons, i.e. 
propranolol for tremor; 3) Doubt or lack of consensus on diagnosis. 
In the present work, 4 SCZ patients and 2 HCs were excluded due to 
arterial hypertension diagnosis and/or use of anti-hypertensive drugs. 8 HCs 
did not provide blood for DNA or the DNA quality was too low for GWAS, and 
therefore, they were excluded. At last, 83 patients and 92 HCs were included. 
 
Blood samples 
Blood samples were collected from all subjects into heparin vacuum 
tubes BD Vacutainer® (BD, NJ, USA). The samples were kept at 4C until 
initial processing, and then centrifuged at 1500-2000g for 10-15 min to 
recover the plasma, which was then aliquoted and stored at -20°C in plastic 
microtubes (Axygen Inc., CA, USA) until use. 
 
Activity measurements 
Ndel1-like activity was measured in human plasma samples of normal 
HC volunteers and SCZ patients, defrosted on ice and then re-aliquoted into 
smaller volumes for a fluorimetric assay, using the FRET peptide substrate 
Abz-GFSPFRQ-EDDnp [10 µM]. Hydrolysis of the substrate, at 37C, was 
monitored by measuring the fluorescence in a Shimadzu RF-5301 PC 
spectrofluorometer at Em = 420 nm and Ex = 320 nm. The 1 cm-pathlength 
cuvette containing 1 mL of substrate solution (50 mM Tris-HCl pH 7.4 and 100 
mM NaCl buffer) was placed in a thermostatically controlled cell compartment 
for 5 min, before the addition of the plasma samples. The increase in 
fluorescence (AFU, arbitrary fluorescence units) with time was continuously 
recorded for 5-10 min, both in the absence and in the presence of 50 µL of a 
heat-inactivated Ndel1 antibody (NOAB inhibitor), as previously described 
(Hayashi et al., 2005). Calculated Ndel1 activity was the rate of hydrolysis in 
the absence of the NOAB inhibitor minus the rate determined in the presence 
of the NOAB inhibitor. 
 
Genetic Procedures 
All participants were genotyped using the Illumina Human Omni Express 
Bead Chip (Illumina, Inc., San Diego, CA, USA). All DNA samples underwent 
stringent quality control including exclusion if sample genotype missing rate 
>1%, or if abnormal heterozygosity or unmatched sex assignment were 
observed. SNPs with minor allele frequency <1% or showing departure from 
Hardy-Weinberg equilibrium (p < 1 × 10-5) were excluded. The 704,523 SNPs 
that passed quality control were imputed to the December 2013 release from 
the 1000 Genomes project [1000 Genomes Consortium, 2012], using 
IMPUTE2 (Howie et al., 2009), with concurrent phasing (no pre-phasing). 
8,793,001 SNPs with an info score > 0.8 and minor allele frequency >1% 
were retained for analyses.  
 
Statistical analysis 
We used GCTA Yang et al. (2011) to perform a genome wide analysis 
(GWAS) using a mixed model approach that adjusts for population 
stratification while carrying out association for each SNP. We derived a 
genetic relationship matrix (GRM) between individuals using the genetic 
marker genotypes on the microarrays to calculate pairwise genomic similarity. 
Individuals whose relationship to another subject was greater than 0.025 
(equal to a fourth cousin) were removed to avoid the possible phenotypic 
similarity between close relatives being due to non-genetic effects, such as 
common environmental effects (Kang et al., 2010). Then we used GCTA’s 
MLMA loco option to generate association results.  
No tool based on a genetic relationship matrix was able to perform 
interaction analyses for genome-wide driven data. Therefore to perform this 
analysis we used PLINK v 1.7 (Purcell et al., 2007). To adjust for population 
stratification, we used a multidimensional scaling approach implemented in 
PLINK that gives equivalent results to principal components analysis (Price et 
al., 2010). The model that corrected for the first 4 dimensions provided the 
best estimates, considering agreement in the first 20 hits, yielded by the 
GCTA major effect analyses. On this basis, we carried out the interaction with 
case status association via a linear model, including an interaction term for 
case status and genotype.  
Genome-wide significance threshold was defined at p < 5 x 10-8 
(Dudbridge and Gusnanto, 2008). For non-genetic tests presented, the 
significance level for standard parametric and non-parametric tests are at 0.05 
level. 
 RESULTS 
No significant difference was found for age, gender or educational level 
between groups (Table 1). Ndel1 enzyme activity levels were significantly 
lower among schizophrenia (SCZ) patients, compared to healthy controls 
(HCs) (t = 4.9; p<0.001), as also described in our previous report (Gadelha et 
al., 2013). There was no significant effect of age, gender, and educational 
level on Ndel1 enzyme activity. 
 
Genomewide Analysis (GWAS) 
In the first set of analyses, we searched for SNPs associated with 
Ndel1 enzyme activity levels, independent of the case status, e.g. SCZ or 
control. Case status was then added to the linear model as a covariate. In 
Table 2, we report the results of analyses with p values <10-6, and the 
Manhattan and QQ plots for the results are depicted (Fig. 1). Taken together, 
no individual SNP was above the GWAS significance threshold. We defined 
as suggestive significance p < 5x10-6, as the standard practise adopted in the 
field. The top ranked findings was for the gene CAMK1D, with two hits and p 
values at 10-6 order. Other genes uncovered with p <10-6 threshold were 
MAGI2, GABGR3, and CCDC25. The NDEL1 gene region was found to have 
very few SNPs and none have reached close to significant or suggestive 
thresholds. 
 
GWAS Interaction 
The results for the interaction term are in Table 2, and they suggest the 
involvement of DYNC1I1, ZFPM2, LINC00371, MAD1L1, The most significant 
results were observed for the region 1p22.2 with p-value of 8.89 x 10-7. 
ZFPM2 and MAD1L1 were the only genes with two SNPs listed above 10-6 
threshold. The Manhattan and QQ plots for the interaction term results are 
depicted in Fig. 2. 
 
  
DISCUSSION 
We sought to understand genetic influences on Ndel1 enzyme activity, 
as we recently found significant lower Ndel1 enzyme activity levels in patients 
with schizophrenia (SCZ) compared to health controls (HCs) (Gadelha et al., 
2013). In the current study, genes that bind to Ndel1 and could potentially 
regulate Ndel1 enzyme activity levels were investigated. We also searched for 
genes that significantly correlated with the observed difference in plasma 
Ndel1 enzyme activity levels between SCZ patients and HCs. We found no 
genome wide significant results, although some suggestive* hits were 
obtained (defining as suggestive p-values <10-6). We found suggestive 
evidence for 4 genes having effects on Ndel1 enzyme activity levels: 
CAMK1D, MAGI2, GABGR3, and CCDC25. In our case status genotype 
interaction analyses, SNPs on region 1p22.2 achieved the most significant p-
values and top hits were at p-level of 10-7. 
The CAMK1D gene, located at chromosome 10p13, encompassing the 
loci with the lowest p-values had a number of suggestive association signals, 
not in linkage disequilibrium, at p-values <10-6. CAMk1D is a Ca2+/calmodulin 
dependent kinase predominantly expressed in polymorphonuclear cells, 
among hematopoietic cell lines (Verploegen et al., 2000). In in vitro assays, 
CAMk1D phosphorylated several substrates, including synapsin 1 and 2, and 
CREB (Nairn and Greengard, 1987; Sheng et al., 1991), which were 
previously associated with SCZ (Fei et al., 2010; Kawanishi et al., 1999; 
Saviouk et al., 2007). The binding of Ca2+ to calmodulin is a signal 
transducing mechanism of Ca2+ into cellular responses that regulate many 
crucial processes (Chin and Means, 2000). Ripke et al. (2013) emphasized 
the potential role of Ca2+ neuronal signalling to SCZ via the observed 
associations at several calcium channel subunit genes, including CACNA1C 
and CACNA1D. 
CAMk1D has been reported to be associated in GWAS meta-analysis 
studies with type II Diabetes (Zeggini et al., 2008) and was later shown to 
reduce glucose response (Grarup et al., 2008), possibly due to an effect on 
the localization of a mediator of both gluconeogenesis and glycolysis (Haney 
et al., 2013). This raises the question about the effect of metabolic process in 
Ndel1 measures and whether they converge to impact on SCZ 
pathophysiology or whether Ndel1 would be only a biomarker of these 
processes. In our first study (Gadelha et al., 2013), we did not observe any 
association between Ndel1 enzyme activity and Body Mass Index (BMI) in a 
subgroup of patients, nor with antipsychotic drug doses in chlorpromazine 
equivalents. However, one cannot rule out any of these possibilities, and they 
should be addressed in future studies. 
MAGI2 has been implicated in both glutamatergic (Deng et al., 2006) 
and GABAergic pathways (Sassoe-Pognetto et al., 2011). SNPs of MAGI2 
have been associated with performance in the Wisconsin Sorting Card Test 
(WCST) in patients with SCZ (Koide et al., 2012), whereas in animal models it 
was shown to modulate long-term memory and associative learning (Emtage 
et al., 2009; Stetak et al., 2009). 
The GABGR3 gene encodes a subunit of the GABA-A receptor and is 
located at chromosome 15q12, inside a locus containing a cluster of other two 
GABA(A) receptor subunit genes, GABRB3 and GABRA5. Despite 
substantive evidence of impaired GABA neurotransmission in SCZ (Wassef et 
al., 2003), no previous study has directly associated GABGR3 to the disorder. 
The 15q11-13 locus has been identified in several CNV studies in SCZ as well 
as in a familial SCZ linkage study (Giusti-Rodriguez and Sullivan, 2013; Liao 
et al., 2012). Kohannim et al. (2012) reported 22 genes associated with 
temporal lobe volume and among them were GABRG3 and MAGI2.  
Our analyses of case control differences using an interaction term 
underwent less stringent ancestry correction and should be interpreted with 
caution. The most significant results were in the 1p22.2 region. A CNV on this 
region has been associated to neurodevelopmental phenotype (Girirajan et 
al., 2011). 1p22 is in a chromosome fragile site, which is believed to constitute 
areas of chromatin that fail to compact during mitosis (Lukusa and Fryns, 
2008). Some recent studies suggested the association between MAD1L1 and 
SCZ and bipolar disorder (Jia et al., 2012; Ruderfer et al., 2014), including 
one of the largest GWAS on SCZ (Ripke et al., 2013). A ZFPM2 
polymorphism (rs12678719) showed to modulate the risk to develop 
antipsychotic-induced parkinsonism in patients with SCZ (Greenbaum et al., 
2012). A point mutation on DYNC1I1 resulted in altered neuronal 
development and elevated anxiety levels in animal model (Banks et al., 2011). 
We did not find any link between LINC00371 and SCZ. 
Considering both set of analyses, several of the genes uncovered by us 
here were previously reported to be expressed or associated with immune 
cells (e.g.CAMK1D, MAGI2), which possibly also suggests the origin of the 
Ndel1 found in plasma (Paik et al., 1992). In the interaction analyses, 
MAD1L1 seems the most promising result for being previously associated in a 
GWAS of SCZ.  
Our small sample size to perform GWAS analyses is the major limitation 
of this work. However, enzyme levels may be a more robust phenotype than 
psychiatric categorical phenotypes. For our analysis of Ndel1 level, the lack of 
significant SNPs tagging the Ndel1 locus indicates that Ndel1 level is likely to 
be a complex, perhaps polygenic, trait. Ndel1 is also essential for normal 
brain development and severe disruption of the protein structure or reduction 
on its physiological levels leads to intrauterine abortion (Sasaki et al., 2005). 
This could explain why Ndel1 enzyme levels appear to a more complex trait 
than, for example, angiotensin I converting enzyme (ACE), other 
oligopeptidase that share common peptide substrates with Ndel1 (Terao et 
al., 2013).  
In a previous study, we worked on ruling out confounding factors, and 
showed that Ndel1 levels were not correlated to the dose of antipsychotics, 
BMI or cigarette smoking (Gadelha et al., 2013). Multiple ancestry admixture 
is a well-know problem dealing with Brazilian samples. For this reason, we 
used GCTA to generate kinship matrix using information in the array to 
perform ancestry correction. It was not possible to apply the same approach 
to the interaction analyses, but of note, our finding of best correction to 4 
principal components is in agreement with a report from Kang et al. (2010), 
where inclusion of 2 to 5 principal components had relevant impact on the 
inflation factor and further augmenting did not result in better genomic control 
of statistical measures. Finally, even with correction for clinical status and 
medication on the main effects analysis, we also cannot rule out that some of 
the findings were driven by SCZ diagnosis. 
Lastly, the genome-wide approach employed here allowed us an 
unbiased investigation on genetic influence on plasma Ndel1 enzyme activity 
measures with new putative genes possibly implicated in SCZ. The relatively 
high significance of genetic variants coding Ndel1 enzyme activity suggests 
that a more precise physiopathology driven hypothesis may increase the 
chances of finding relevant genes to SCZ. Future larger studies focused on 
understanding the involvement of such genes may help to clarify the role of 
Ndel1 expression and activity in SCZ pathophysiology. 
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LEGENDS 
 
Figure 1. Results of Ndel1 enzyme activity versus GWAS – major effects. 
A) Manhattan Plot depicting observed p-values by chromosome. B) QQ plot of 
observed x expected p-values. 
 
Figure 2. Results of Ndel1 enzyme activity versus GWAS – interaction 
term results. A) Manhattan Plot depicting observed p values by 
chromosome. B) QQ plot of observed versus expected p-values. 
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Male 56 (67.5) 60 (65.2)
>10
a 24 (28.9) 27 (29.3)
Age, Mean Years 86 (34.92) 100 -34 -0.612 0.541
Test 
value
0.011
a = years of education
Educational 
level <10
a 59 (71.1) 65 (70.7)
0.753
0.004 0.950
Gender
p-value
Female 27
Table 1. Sociodemographic characteristics.
Patients
(n=83)
Healthy Controls 
(n=92)
Statistics
(32.5) 32 (34.8)
N (%) N (%)
  
 
SNP Region Beta P-value Gene 
rs10184029 2p24 -0.535205 2.78 x 10
-6 No gene
rs4495787 10p13 -0.322829 2.88 x 10
-6 CAMK1D
rs63439260 10p13 -0.330936 2.91 x 10
-6 CAMK1D
rs1190669 18p11 -0.335355 3.37 x 10
-6 No gene
rs564499 18p11 -0.329733 3.46 x 10
-6 No gene
rs515503 18p11 -0.334274 4.39 x 10
-6 No gene
rs62111833 2p24 -0.642179 4.84 x 10
-6 No gene
rs72787916 2p24 -0.59675 5.39 x 10
-6 No gene
rs7902494 10p13 -0.307938 5.53 x 10
-6 CAMK1D
rs2704367 2q24.3 0.29847 5.69 x 10
-6 No gene
rs2615325 2q24.3 0.298237 5.79 x 10
-6 No gene
rs8041484 15q24 -0.36779 5.87 x 10
-6 No gene
rs17439060 7q21 0.3279 6.12 x 10
-6 MAGI2
rs2941397 6p21 -0.37646 6.30 x 10
-6 No gene
rs17439102 7q21 0.299595 6.69 x 10
-6 MAGI2
rs10906183 10p13 -0.31853 6.76 x 10
-6 CAMK1D
rs1075587 8p21 -0.344483 7.22 x 10
-6 No gene
rs59405048 15q12 -0.363503 7.23 x 10
-6 GABRG3
rs140459790 15q12 -0.354705 7.86 x 10
-6 GABRG3
rs35767880 8p21.1 -0.324939 9.17 x 10
-6 CCDC25
rs4887557 15q12 -0.365408 9.51 x 10
-6 GABRG3
Table 2. Top Results for genome-wide investigation of Ndel1 plasma 
CHR SNP BP A1 Beta Stat P Region Gene
1 rs4526597 91064319 C -0.7466 -5.173 6,91E-07 1p22.2 No gene
1 rs479169 91035731 C -0.7682 -5.129 8,89E-07 1p22.2 No gene
1 rs7418693 91068580 T -0.7234 -5.017 1,39E-06 1p22.2 No gene
1 rs6428591 91066089 A -0.7177 -4.972 1,70E-06 1p22.2 No gene
1 rs10801818 91068211 T -0.7092 -4.924 2,12E-06 1p22.2 No gene
11 rs1752232 35875195 T -1.056 -4.989 2,18E-06 11p13 No gene
10 rs4526672 66926880 T 0.5951 4.851 2,90E-06 10q21.3 No gene
1 rs10922882 91053707 C -0.6918 -4.82 3,27E-06 1p22.2 No gene
7 rs7808673 95532968 T -0.6968 -4.782 4,01E-06 7q21.3 DYNC1I1
8 rs7836133 106747160 T -0.607 -4.76 4,26E-06 8q23.1 ZFPM2
7 rs4721188 1953615 G -0.7879 -4.747 4,75E-06 7p22.3 MAD1L1
13 rs142345263 51746239 G 0.7771 4.758 4,93E-06 13q14.3 LINC00371
10 rs4745861 66927624 G -0.627 -4.725 5,10E-06 10q21.3 No gene
8 rs11997907 19992955 A 0.741 4.712 5,24E-06 8p21.3 No gene
8 rs10808406 106724356 G -0.6173 -4.709 5,57E-06 8q23.1 ZFPM2
10 rs4317873 66925741 T -0.6239 -4.686 6,00E-06 10q21.3 No gene
7 rs111698506 1977834 A -0.8773 -4.682 6.67e-06 7p22.3 MAD1L1
12 rs78870100 25904029 T 1.098 4.596 8,95E-06 12p12.1 No gene
8 rs1025856 106733869 G -0.5911 -4.578 9,36E-06 8q23.1 ZFPM2
Table 3. Top results for genome-wide results for Ndel1 plasma enzyme activity/clinical status interaction.
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